FindTrial
Sign In

Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)

Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030773
Enrollment
Unknown
Registered
2020-03-14
Start date
2020-02-12
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:Early initiation of blood purification

Sponsors

Huashan Hospital Fudan Universtiy
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Diagnosed as COVID-19 pneumonia (according to the latest diagnostic criteria of The novel coronavirus pneumonia diagnosis and treatment plan formulated by the State Health Protection Committee); 3. admitted into ICU; 4. Rapid increase of serum IL-6 level.

Exclusion criteria

Exclusion criteria: 1. Renal replacement therapy has been performed; 2. Relative / absolute contraindications of blood purification; 3. Pregnant women, participating in other clinical trials, etc.

Design outcomes

Primary

MeasureTime frame
death;Number of failure organs;Length of hospital stay;—

Secondary

MeasureTime frame
SOFA score, APACHE II score;time of mechanical ventilation;Complications related to blood purification;—

Countries

China

Contacts

Public ContactJing Chen

Huashan Hospital Fudan University

money_0921@163.com+86 13816108686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026